Femasys Inc. (FEMY) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Instruments & Supplies 行业. 公司总部位于 Suwanee, GA, 美国. 现任CEO为 Kathy Lee-Sepsick.
FEMY 拥有 IPO日期为 2021-06-18, 69 名全职员工, 在 NASDAQ Capital Marke, 市值为 $12.63M.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
